PARP1 and neoplasm: Tumor BRCA testing (tBRCA) is emerging as a powerful tool to discover and identify more mutations in high serous ovarian cancer patients which have been shown to benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors [1, 2].